A challenging diagnosis for potential fatal diseases: Recommendations for diagnosing acute porphyrias

European Journal of Internal Medicine

Volumn 25, Issue 6, 2014, Pages 497-505

  Ventura, Paolo ^a   Cappellini, Maria Domenica ^b   Biolcati, Gianfranco ^c   Guida, Claudio Carmine ^d   Rocchi, Emilio ^a   Graziadei, G ^b   Di Pierro, E ^b   Brancaleoni, V ^b   Granata, F ^b   Marchini, S ^a   Pietrangelo, A ^a   Macri A ^c   Barbieri, L ^c   Lupia Palmieri, G ^c   Iacopini, S ^c   Pitisci, A ^c   Aurizi, C ^c   Sorge, F ^c   Savino, M ^d   Aucella, F ^d   Di Mauro, L ^d   more..

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Acute porphyrias; Acute porphyric attack; Biochemical; Diagnosis; Differential diagnosis; Lead intoxication

Indexed keywords

AMINOLEVULINIC ACID; COPROPORPHYRIN; HORMONE; PORPHOBILINOGEN; PORPHOBILINOGEN SYNTHASE; PROTOPORPHYRIN; UROPORPHYRIN;

ACUTE INTERMITTENT PORPHYRIA; ALCOHOL ABUSE; CALORIC RESTRICTION; CLINICAL FEATURE; COPROPORPHYRIA; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ELECTROLYTE DISTURBANCE; ENVIRONMENTAL FACTOR; ENZYME DEFICIENCY; ERYTHROCYTE; FAMILY HISTORY; FECES ANALYSIS; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFECTION; LABORATORY DIAGNOSIS; LEAD POISONING; MEDICAL SPECIALIST; MENTAL DISEASE; PENETRANCE; PHYSICIAN; PLUMBOPORPHYRIA; PORPHOBILINOGEN SYNTHASE DEFICIENCY PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; REVIEW; SPECTROPHOTOMETRY; URINALYSIS; ABDOMINAL PAIN; COMPLICATION; COPROPORPHYRIA, HEREDITARY; DEFICIENCY; NAUSEA; PORPHYRIA, ACUTE INTERMITTENT; PORPHYRIA, VARIEGATE; PRACTICE GUIDELINE; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; VOMITING;

ABDOMINAL PAIN; COPROPORPHYRIA, HEREDITARY; HUMANS; LEAD POISONING; NAUSEA; PORPHOBILINOGEN SYNTHASE; PORPHYRIA, ACUTE INTERMITTENT; PORPHYRIA, VARIEGATE; PRACTICE GUIDELINES AS TOPIC; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; VOMITING;

EID: 84903377127     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.03.011     Document Type: Review

References (115)

1. Ventura P, Cappellini MD, Rocchi E. The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med 2009;4:297–308.
2. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet 2010;375:924–37.
3. Porphyrias Kauppinen R. Lancet 2005;365:241–52.
4. Thunell S. Porphyrins, porphyrin metabolism and porphyrias. I Update. Scand J Clin Lab Invest 2000;60:509–40.
5. Ventura P. Le Porfirie. In: Brunetti P, Santeusanio F, editors. Trattato di Medicina Interna. Volume Malattie delle Ghiandole Endocrine, del Metabolismo e della Nutrizione. Padova: Piccin Nuova Libraria; 2011. p. 931–52.
6. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. Lancet 1997;349:1613–7.
7. Bonkovsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 1998;18:57–65.
8. de Rooij WM, Edixhoven A, Wilson JH. Porphyria: a diagnostic approach. In: Kadish KM, Smith KM, Guillard R, editors. The porphyrin handbook. St Louis: Elsevier; 2003. p. 211–45.
9. Anderson KE, Sassa S, Kappas A. Acute intermittent porphyria. Ann Intern Med 1981;95:784–5.
10. Grandchamp B. Acute intermittent porphyria. Semin Liver Dis 1998;18:17–24.
11. Herrick A, McColl KE, McLellan A, Moore MR, Brodie MJ, Goldberg A. Effect of haem arginate therapy on porphyrin metabolism and mixed function oxygenase activity in acute hepatic porphyria. Lancet 1987;2:1178–9.
12. Herrick AL, McColl KE, Moore MR, Cook A, Goldberg A. Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1989;1:1295–7.
13. Elder GH, Hift RJ. Treatment of acute porphyria. Hosp Med 2001;62:422–5.
14. Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. Am J Med 2006;119:801.e19–24.
15. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;142:439–50.
16. Elder GH. Enzymatic defects in porphyria: an overview. Semin Liver Dis 1982;2:87–99.
17. Elder GH. Update on enzyme and molecular defects in porphyria. Photodermatol Photoimmunol Photomed 1998;14:66–9.
18. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudet A, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited diseases. New York: McGraw-Hill; 2001. p. 2991–3062.
19. Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the ‘Royal Malady’. J Clin Pathol 2012;65:200–5.
20. Kirsch RE, Meissner PN, Hift RJ. Variegate porphyria. Semin Liver Dis 1998;18: 33–41.
21. Di Pierro E, Ventura P, Brancaleoni V, Moriondo V, Marchini S, Tavazzi D, et al. Clinical, biochemical and genetic characteristics of variegate porphyria in Italy. Cell Mol Biol (Noisy-le-Grand) 2009;55:79–88.
22. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005;84:48–60.
23. Martasek P. Hereditary coproporphyria. Semin Liver Dis 1998;18:25–32.
24. Ventura E, Rocchi E. Le Porfirie. In: Guarini G, Fiorelli G, Malliani A, Violi E, Volpe M, editors. Teodori 2000. Trattato di Medicina Interna. Volume 2. 6th ed. Roma: Società Editrice Universo; 2001. p. 2301–34.
25. Sassa S. ALAD porphyria. Semin Liver Dis 1998;18:95–101.
26. Warren MJ, Cooper JB, Wood SP, Shoolingin-Jordan PM. Lead poisoning, haem synthesis and 5-aminolaevulinic acid dehydratase. Trends Biochem Sci 1998;23:217–21.
27. Herman DS, Geraldine M, Venkatesh T. Evaluation, diagnosis, and treatment of lead poisoning in a patient with occupational lead exposure: a case presentation. J Occup Med Toxicol 2007;2:7.
28. Orphanet Report Series. Prevalence of rare diseases; bibliographic data. Available at http://www.orpha.net/orphacom/cahiiers/docs/GB/Prevalence:of_rare_diseases_by_alphabetical_list.pdf; 2010.
29. Mustajoki P, Koskelo P. Hereditary hepatic porphyrias in Finland. Acta Med Scand 1976;200:171–8.
30. Mustajoki P. Variegate porphyria. Twelve years' experience in Finland. Q J Med 1980;49:191–203.
31. Meissner PN, Meissner DM, Sturrock ED, Davidson B, Kirsch RE. Porphyria—the UCT experience. S Afr Med J 1987;72:755–61.
32. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988;57:117–20.
33. Nordmann Y, Puy H, Da Silva V, Simonin S, Robreau AM, Bonaiti C, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med 1997;242:213–7.
34. Floderus Y, Shoolingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 2002;62:288–97.
35. von und zu Fraunberg M, Pischik E, Udd L, Kauppinen R. Clinical and biochemical characteristics and genotype–phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine (Baltimore) 2005;84:35–47.
36. von und zu Fraunberg M, Tenhunen R, Kauppinen R. Expression and characterization of six mutations in the protoporphyrinogen oxidase gene among Finnish variegate porphyria patients. Mol Med 2001;7:320–8.
37. von und zu Fraunberg M, Timonen K, Mustajoki P, Kauppinen R. Clinical and biochemical characteristics and genotype–phenotype correlation in Finnish variegate porphyria patients. Eur J Hum Genet 2002;10:649–57.
38. Thunell S, Floderus Y, Henrichson A, Harper P. Porphyria in Sweden. Physiol Res 2006;55:S109–18.
39. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis 2013;36:849–57.
40. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 1992;71:1–13.
41. Hift RJ, Meissner D, Meissner PN. A systematic study of the clinical and biochemical expression of variegate porphyria in a large South African family. Br J Dermatol 2004;151:465–71.
42. Waldenstrom J, Haeger-Aronsen B. Different patterns of human porphyria. Br Med J 1963;2:272–6.
43. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierach CA, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 1996;65:269–73.
44. Lamon J, With TK, Redeker AG. The Hoesch test: bedside screening for urinary porphobilinogen in patients with suspected porphyria. Clin Chem 1974;20:1438–40.
45. Thunell S, Harper P, Brock A, Petersen NE. Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scand J Clin Lab Invest 2000;60:541–59.
46. Crimlisk HL. The little imitator–porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997;62:319–28.
47. Massey EW. Neuropsychiatric manifestations of porphyria. J Clin Psychiatry 1980;41:208–13.
48. Santosh PJ, Malhotra S. Varied psychiatric manifestations of acute intermittent porphyria. Biol Psychiatry 1994;36:744–7.
49. Ellencweig N, Schoenfeld N, Zemishlany Z. Acute intermittent porphyria: psychosis as the only clinical manifestation. Isr J Psychiatry Relat Sci 2006;43:52–6.
50. Gupta GL, Saksena HC, Gupta BD. Cardiac dysautonomia in acute intermittent porphyria. Indian J Med Res 1983;78:253–6.
51. O'Mahoney D, Wathen CG. Hypertension in porphyria—an understated problem. QJM 1996;89:161–2.
52. Solinas C, Vajda FJ. Neurological complications of porphyria. J Clin Neurosci 2008;15:263–8.
53. Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-Grand) 2009;55:72–83.
54. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998;18:43–52.
55. Usalan C, Erdem Y, Altun B, Gursoy M, Celik I, Yasavul U, et al. Severe hyponatremia due to SIADH provoked by acute intermittent porphyria. Clin Nephrol 1996;45:418.
56. Frere T, Roy-Peaud F, Ripault MP, Dumas P, Silvain C, Pourrat O, et al. Acute intermittent porphyria associated with hyperaldosteronism and inappropriate antidiuretic hormone secretion syndrome. Gastroenterol Clin Biol 1998;22:727–31.
57. Kuhnel A, Gross U, Doss MO. Hereditary coproporphyria in Germany: clinical–biochemical studies in 53 patients. Clin Biochem 2000;33:465–73.
58. Deacon AC. Performance of screening tests for porphyria. Ann Clin Biochem 1988;25:392–7.
59. Hindmarsh JT. The porphyrias, appropriate test selection. Clin Chim Acta 2003;333:203–7.
60. Andersson C, Thunell S, Floderus Y, Forsell C, Lundin G, Anvret M, et al. Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods. J Intern Med 1995;237:301–8.
61. Disler PB, Eales L. The acute attack of porphyria. S Afr Med J 1982;61:82–4.
62. Henderson MJ. Thin-layer chromatography of free porphyrins for diagnosis of porphyria. Clin Chem 1989;35:1043–4.
63. Hift RJ. The diagnosis of porphyria. S Afr Med J 1999;89:611–4.
64. Hift RJ, Davidson BP, van der Hooft C, Meissner DM, Meissner PN. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem 2004;50:915–23.
65. Lai CK, Lam CW, Chan YW. High-performance thin-layer chromatography of free porphyrins for diagnosis of porphyria. Clin Chem 1994;40:2026–9.
66. Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-Grand) 2009;55:66–71.
67. Sardh E, Harper P, Andersson DE, Floderus Y. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med 2009;20:201–7.
68. With TK. Simple and rapid screening for acute porphyria—‘porphobilistix’ and Hoesch test. S Afr Med J 1971:229–30.
69. Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998;35:726–32.
70. McEwen J, Paterson C. Drugs and false-positive screening tests for porphyria. Br Med J 1972;1:421.
71. Beard D. Plumbo porphyria. A difficult diagnosis. Occup Health (Lond) 1993;45:25.
72. Frith D, Yeung K, Thrush S, Hunt BJ, Hubbard JG. Lead poisoning—a differential diagnosis for abdominal pain. Lancet 2005;366:2146.
73. Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, et al. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. Br J Haematol 2006;132:237–43.
74. Chan KM, Ladenson JH, Vaidya HC, Kanan R. Washington University case conference. Dual porphyria—an underdiagnosed entity? Clin Chem 1987;33:1190–3.
75. Sies C, Florkowski C, George P, Potter H. Clinical indications for the investigation of porphyria: case examples and evolving laboratory approaches to its diagnosis in New Zealand. N Z Med J 2005;118:U1658.
76. Grob U, Puy H, Jacob K, Deybach JC, Kremer J, Doss MO. Biochemical compared to molecular diagnosis in acute intermittent porphyria. J Inherit Metab Dis 2006;29: 157–61.
77. Campbell BC, Brodie MJ, Thompson GG, Meredith PA, Moore MR, Goldberg A. Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. Clin Sci Mol Med 1977;53:335–40.
78. Ostrowski J, Kosecki P, Martynska M, Milewski B. Urinary porphyrins in liver disease. Scand J Gastroenterol 1984;19:862–6.
79. Koskelo P, Mustajoki P. Altered coproporhyrin-isomer excretion in patients with the Dubin–Johnson syndrome. Int J Biochem 1980;12:975–8.
80. Frank M, Doss MO. Relevance of urinary coproporphyrin isomers in hereditary hyperbilirubinemias. Clin Biochem 1989;22:221–2.
81. Rocchi E, Gibertini P, Santunione V, Balli F, Ventura E. Faecal and urinary coproporphyrin isomers in biliary atresia and neonatal hepatitis. Ric Clin Lab 1980;10:501–9.
82. Rocchi E, Balli F, Gibertini P, Trenti T, Pietrangelo A, Cassanelli M, et al. Coproporphyrin excretion in healthy newborn babies. J Pediatr Gastroenterol Nutr 1984;3:402–7.
83. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 1997;65:235–51.
84. Strife CF, Zuroweste EL, Emmett EA, Finelli VN, Petering HG, Berry HK. Tyrosinemia with acute intermittent porphyria: aminolevulinic acid dehydratase deficiency related to elevated urinary aminolevulinic acid levels. J Pediatr 1977;90:400–4.
85. Moore MR, Graham DJ. Monopyrroles in porphyria, psychosis and lead exposure. Int J Biochem 1980;12:827–32.
86. Oberndorfer S, Hitzenberger P, Gruber W, Seidel J, Urbanits S, Doss M, et al. Secondary coproporphyrinuria in a patient with the full clinical picture of a hereditary acute hepatic porphyria. A misleading clinical and biochemical course. J Neurol 2002;249:1325–6.
87. Maruno M, Furuyama K, Akagi R, Horie Y, Meguro K, Garbaczewski L, et al. Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood 2001;97:2972–8.
88. Aarsand AK, Petersen PH, Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem 2006;52:650–6.
89. Sassa S. Diagnosis and therapy of acute intermittent porphyria. Blood Rev 1996;10: 53–8.
90. Erlandsen EJ, Jorgensen PE, Markussen S, Brock A. Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements. Scand J Clin Lab Invest 2000;60: 627–34.
91. Gross U, Jacob K, Frank M, Doss MO. Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria. Cell Mol Biol (Noisy-le-Grand) 1997;43:29–35.
92. Pierach CA, Weimer MK, Cardinal RA, Bossenmaier IC, Bloomer JR. Red blood cell porphobilinogen deaminase in the evaluation of acute intermittent porphyria. JAMA 1987;257:60–1.
93. Garcia Plaza A, Espana Saz P, Escartin Marin P, Diego Marin FJ, Criado Ortiz M. Treatment of porphyria hepatica cutanea tarda by bloodletting (experience in 10 cases). Rev Clin Esp 1973;131:477–84.
94. De Siervi A, Varela LS, Parera VE, Batlle AM, Rossetti MV. Diagnosis of latent acute intermittent porphyria by genetic analysis. Ann Clin Biochem 2001;38:149–52.
95. Puy H, Aquaron R, Lamoril J, Robreau AM, Nordmann Y, Deybach JC. Acute intermittent porphyria: rapid molecular diagnosis. Cell Mol Biol (Noisy-le-Grand) 1997;43: 37–45.
96. Di Pierro E, Brancaleoni V, Besana V, Cappellini MD. Multiplex ligation-dependent probe amplification: a novel approach for genetic diagnosis of Porphyria. J Hum Genet 2009;54:479–87.
97. Martinez di Montemuros F, Di Pierro E, Biolcati G, Rocchi E, Bissolotti E, Tavazzi D, et al. Acute intermittent porphyria: heterogeneity of mutations in the hydroxymethylbilane synthase gene in Italy. Blood Cells Mol Dis 2001;27:961–70.
98. Martinez di Montemuros F, Di Pierro E, Fargion S, Biolcati G, Griso D, Macri A, et al. Molecular analysis of the hydroxymethylbilane synthase (HMBS) gene in Italian patients with acute intermittent porphyria: report of four novel mutations. Hum Mutat 2000;15:480.
99. Ulbrichova D, Hrdinka M, Saudek V, Martasek P. Acute intermittent porphyria– impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. FEBS J 2009;276:2106–15.
100. Lee JS, Anvret M, Lindsten J, Lannfelt L, Gellerfors P, Wetterberg L, et al. DNA polymorphisms within the porphobilinogen deaminase gene in two Swedish families with acute intermittent porphyria. Hum Genet 1988;79:379–81.
101. Blake D, McManus J, Cronin V, Ratnaike S. Fecal coproporphyrin isomers in hereditary coproporphyria. Clin Chem 1992;38:96–100.
102. With TK. Hereditary coproporphyria and variegate porphyria in Denmark. Dan Med Bull 1983;30:106–12.
103. Sasaki H, Kaneko K, Tsuneyama H, Daimon M, Yamatani K, Manaka H. Family study of acute intermittent porphyria and hereditary coproporphyria in Niigata and Akita Prefectures, Japan. J Clin Epidemiol 1996;49:1117–23.
104. Meissner PN, Day RS, Moore MR, Disler PB, Harley E. Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate porphyria. Eur J Clin Invest 1986;16:257–61.
105. Deybach JC, Puy H, Robreau AM, Lamoril J, Da Silva V, Grandchamp B, et al. Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. Hum Mol Genet 1996;5:407–10.
106. Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigall AV, Roberts AG, et al. AR59Wmu-tation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 1996;13:95–7.
107. Whatley SD, Puy H, Morgan RR, Robreau AM, Roberts AG, Nordmann Y, et al. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet 1999;65:984–94.
108. Frank J, Jugert FK, Merk HF, Kalka K, Goerz G, Anderson K, et al. A spectrum of novel mutations in the protoporphyrinogen oxidase gene in 13 families with variegate porphyria. J Invest Dermatol 2001;116:821–3.
109. Frank J, Aita VM, Ahmad W, Lam H, Wolff C, Christiano AM. Identification of a founder mutation in the protoporphyrinogen oxidase gene in variegate porphyria patients from chile. Hum Hered 2001;51:160–8.
110. Meissner PN, Corrigall AV, Hift RJ. Fifty years of porphyria at the University of Cape Town. S Afr Med J 2012;102:422–6.
111. Gorchein A. Drug treatment in acute porphyria. Br J Clin Pharmacol 1997;44: 427–34.
112. Magnus IA. Drugs and porphyria. Br Med J (Clin Res Ed) 1984;288:1474–5.
113. Mamet R, Schoenfeld N. A reliable diagnosis of porphyria should precede any conclusion concerning the safety of a drug in porphyria. Anesthesiology 1999;91: 583–4.
114. Stolzel U, Brosche C, Koszka C, Stauch T, Teubner A, Doss MO. Safe and probably safe drugs in acute hepatic porphyria. Cell Mol Biol (Noisy-le-Grand) 2009;55: 147–51.
115. Hindmarsh JT, Oliveras L, Greenway DC. Biochemical differentiation of the porphyrias. Clin Biochem 1999;32:609–19.